We are live on ! Find out more
BEAM icon

Beam Therapeutics

221 hedge funds and large institutions have $2.32B invested in Beam Therapeutics in 2024 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 80 increasing their positions, 47 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

206% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 18

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

70% more repeat investments, than reductions

Existing positions increased: 80 | Existing positions reduced: 47

19% more funds holding

Funds holding: 185221 (+36)

17% more capital invested

Capital invested by funds: $1.99B → $2.32B (+$333M)

3.57% less ownership

Funds ownership: 89.71%86.14% (-3.6%)

53% less call options, than puts

Call options by funds: $13.8M | Put options by funds: $29.1M

Holders
221
Holders Change
+36
Holders Change %
+19.46%
% of All Funds
3.18%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.04%
New
55
Increased
80
Reduced
47
Closed
18
Calls
$13.8M
Puts
$29.1M
Net Calls
-$15.4M
Net Calls Change
-$19.6M

BEAM Hedge Fund Activity: Q1 2024 in Review

221 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q1 2024, worth a combined $2.32B — up 17% from $1.99B a quarter earlier.

Buyers outnumbered sellers: 55 funds opened new BEAM positions and 18 closed out — a net gain of 37 holders — while 80 added to existing stakes and 47 trimmed.

The largest buyer was Darwin Global Management, opening a new position worth an estimated $66M. The largest seller was Morgan Stanley, cutting an estimated $132M.

  • 221 institutional investors held Beam Therapeutics (BEAM) as of Q1 2024, up from 185 in Q4 2023.
  • Funds reported $2.32B of Beam Therapeutics stock for Q1 2024, up 17% quarter-over-quarter.
  • 55 funds opened new Beam Therapeutics positions in Q1 2024 and 18 closed out, a net change of +37 holders.
  • The largest Beam Therapeutics buyer in Q1 2024 was Darwin Global Management, an estimated $66M added.
  • The largest Beam Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $132M sold.

Based on aggregated 13F filings for Q1 2024.